/
Neurology
Seizure
16
Pipeline Programs↗
26
Active Trials↗
32
Companies Involved↗
Seizure is an emerging landscape with 16 programs across 32 companies. The most active players are GRIN Therapeutics, Inc., Rapport Therapeutics Inc., Praxis Precision Medicines. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 1
No programs
Phase 24
Phase 34
Approved
No programs
Analysis
Trial Status
284
clinical trials
Completed203 · 71%
Terminated40 · 14%
Recruiting19 · 7%
Withdrawn9 · 3%
Not yet recruiting5 · 2%
Unknown status5 · 2%
Other3 · 1%
Clinical Trials
Trial Activity
284 trials
A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures
Recruiting·—·Phase 4·NCT06967012·30 enrolled
Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)
Recruiting·—·Phase 4·NCT07072624·1,260 enrolled
Page 1 of 19
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)